In a multicenter, open-label, single-arm, phase 2 basket trial by Subbiah et al., investigators examined the use of dabrafenib (BRAF inhibition) and trametinib (MEK 1/2 inhibition) in the setting of recurrent/progressive BRAF V600E-mutant gliomas (NCT02034110). Here, MAP2K1 is linked to central nervous system cancer.